CI-1021

CI-1021 is a chemical compound that has been investigated for its potential use in the treatment of various medical conditions. It is primarily known as a selective antagonist of the neurokinin-1 receptor (NK1 receptor), which is involved in the modulation of pain and inflammation, as well as the regulation of mood and anxiety.

Pharmacology

CI-1021 functions by blocking the action of substance P, a neuropeptide that binds to the NK1 receptor. Substance P is associated with the transmission of pain signals and the regulation of emotional responses. By inhibiting this interaction, CI-1021 may reduce pain and have anxiolytic effects.

Clinical Research

Research into CI-1021 has focused on its potential applications in treating conditions such as chronic pain, depression, and anxiety disorders. However, as of the latest updates, CI-1021 has not been approved for clinical use, and its development status remains uncertain.

Mechanism of Action

The NK1 receptor is a G-protein coupled receptor that, when activated by substance P, initiates a cascade of intracellular events leading to the sensation of pain and the modulation of mood. CI-1021, by acting as an antagonist, prevents these effects by blocking the receptor.

Potential Applications

• Pain Management: CI-1021 has been studied for its potential to alleviate chronic pain conditions by interfering with the pain signaling pathways.
• Psychiatric Disorders: Due to its effects on mood regulation, CI-1021 has been explored as a treatment for depression and anxiety.

Safety and Efficacy

The safety profile of CI-1021 has been evaluated in preclinical studies, but comprehensive clinical trials are necessary to establish its efficacy and safety in humans. Potential side effects and long-term impacts remain areas of active research.

Also see

• Neurokinin-1 receptor antagonist
• Substance P
• Chronic pain management
• Anxiolytic